Abstract
Background:
Chronic obstructive pulmonary disease (COPD) greatly affects quality of life (QoL). Although QoL is a key concern for the patient, primary endpoints in most clinical trials are objective measures of disease progression.
Methods:
A systematic review of double-blind randomised controlled trials was undertaken to identify data relating to the effect of tiotropium on QoL in patients with COPD.
Results:
A total of 24 publications met the inclusion criteria. Compared with placebo, in the majority of studies tiotropium statistically significantly improved the St George's Respiratory Questionnaire (SGRQ) total score, although improvement beyond the accepted minimum clinically important difference (MCID) of 4 units was only achieved in three studies, all of which were of less than nine months' duration. Tiotropium also statistically significantly improved the Transition Dyspnoea Index (TDI) focal score, equating to clinically meaningful improvements, in almost all the studies that assessed TDI. In general, higher proportions of patients receiving tiotropium achieved clinically meaningful responses. The addition of other therapies (dual therapy, triple therapy) to tiotropium provided benefits that exceeded the SGRQ MCID and provided further benefit with regard to the TDI.
Conclusions:
Tiotropium improves QoL for patients with COPD requiring long-acting bronchodilators, with other additional therapies providing further benefits, depending on the population.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AK is part of the speakers bureau for AstraZeneca, GlaxoSmithKline, Talecris, Boehringer Ingelheim, Nycomed, Pfizer, and Purdue and has received funding for meeting attendance from AstraZeneca and Merck Frosst. AK is on advisory boards for Merck Frosst, Novartis, Purdue, and AstraZeneca; on the Health Canada section of Allergic and Respiratory Therapeutics; also on the Public Health Agency of Canada respiratory surveillance committee.
Rights and permissions
About this article
Cite this article
Kaplan, A. Effect of tiotropium on quality of life in COPD: a systematic review. Prim Care Respir J 19, 315–325 (2010). https://doi.org/10.4104/pcrj.2010.00067
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4104/pcrj.2010.00067
This article is cited by
-
A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
BMC Pulmonary Medicine (2016)
-
Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease
Journal of Huazhong University of Science and Technology [Medical Sciences] (2011)